Table 1 |
|||
|
Cytokine-targeting agents and their clinical trials in SLE |
|||
|
Cytokine target |
Therapeutic agent |
Stage of clinical trial |
References |
|
|
|||
|
IL-6 |
Tocilizumab |
Phase I |
[24] |
|
TNFα |
Infliximab, etanercept |
Phase I; phase II and III trials terminated prematurely |
|
|
IFNα |
Sifalimumab (MEDI-545), rontalizumab (rhuMab) |
Phase I; phase II ongoing |
|
|
BLyS |
Belimumab |
Phase III completed |
|
|
A-623 |
Phase I; phase II suspended/restarted |
[123] |
|
|
LY2127399 |
Phase III planned |
[125] |
|
|
BLyS and APRIL |
Atacicept |
Phase II/III initiated |
[122] |
|
|
|||
|
Jacob and Stohl Arthritis Research & Therapy 2011 13:228 doi:10.1186/ar3349 |
|||